http://nfmod.newell-fonda.k12.ia.us/inde... http://nfmod.newell-fonda.k12.ia.us/inde... viagra tabletten teilen
comprar cialis generico en barcelona 
combien coute de viagra en france 
http://www.mica.edu.vn/?cmJ=G3281&cmC=46... 
cialis a basso prezzo vente viagra pfizer achat cialis en martinique
    génériques viagra achat cialis en ligne achat viagra en ligne en france
    http://web.taftcollege.edu/gasb/gasb2/dl... comprar viagra online cialis sur internet
levitra generico precio trouver du viagra tadalafil precio

Neoadjuvant chemo does not improve oral cancer survival rates

Sun, Nov 11, 2012

Oral Cancer News

Source: www.drbicuspid.com
Author: DrBicuspid Staff

Patients with advanced resectable oral squamous cell carcinoma (OSCC) who undergo surgery do not benefit from improved survival after induction with docetaxel, cisplatin, and fluorouracil (TPF), according to a new study (Journal of Clinical Oncology, November 5, 2012). Study author Zhi-yuan Zhang, MD, PhD, from Shanghai Jiao Tong University School of Medicine, and colleagues assessed 256 patients with resectable locally advanced OSCC.

A total of 222 patients completed the full treatment protocol. They received two cycles of TPF induction chemotherapy (75 mg/m2 of docetaxel on day 1, 75 mg/m2 of cisplatin on day 1, and 750 mg/m2 of fluorouracil on days 1 to 5) followed by radical surgery and postoperative radiotherapy versus upfront radical surgery and postoperative radiotherapy.

The primary end point was overall survival. Secondary end points included local control and safety.

After a median follow-up of 30 months, there was no significant difference in overall survival or disease-free survival between patients treated with or without TPF induction, the study authors noted. Patients in the induction chemotherapy arm with a clinical response or favorable pathologic response had superior overall survival and locoregional and distant control.

“Our study failed to demonstrate that TPF induction chemotherapy improves survival compared with upfront surgery in patients with resectable stage III or IVA OSCC,” the authors concluded.

The lack of survival benefit indicates that TPF induction chemotherapy without selection could not benefit OSCC patients in general, Dr. Zhang told Reuters Health in a news story.

“On the other hand, superior outcomes are seen in responders, as assessed both by clinical and pathologic responses,” he said. “Therefore, induction chemotherapy is likely to be effective for biologically distinct subgroups, and biomarker development might lead to identification of patients whose tumors are likely to respond to a particular treatment.”

Print Friendly
Be Sociable, Share!
, , , , , ,

Leave a Reply

You must be logged in to post a comment.